Yijuan Zhang

This study identifies SAA1-TLR4 signaling as a tumor-derived pathway driving muscle wasting in pancreatic cancer, showing that targeting this pathway can preserve muscle mass and improve survival without affecting tumor growth.

The paper identifies SBP-1750, a ULK inhibitor that degrades ATG13 and kills KRAS-mutant cancer cells, showing efficacy in vivo and immune enhancement.

This study shows that disabling PSGL-1 enhances anti-tumor immunity in pancreatic cancer by improving CD8+ T cell function and response to PD-1 blockade.

This study shows that aging stromal cells in pancreatic cancer promote immune exclusion and metastasis, and that rejuvenating these cells can reverse these effects.

This study shows that macropinocytosis regulates CAF subtype identity under metabolic stress in PDAC, impacting tumor stroma and therapeutic response.